Dexmedetomidine for Sedation During Radiological Interventional Procedures
Phase 4
Completed
- Conditions
- Procedural Sedation
- Interventions
- Drug: Dexmeditomedine
- Registration Number
- NCT02180737
- Lead Sponsor
- National Cancer Institute, Egypt
- Brief Summary
Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Age from 18-65 years old
- ASA physical status of I-II
- Expected procedure lasting at least 30 minutes
Exclusion Criteria
- Unstable cardiac status (life-threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction and third-degree heart block.
- An alpha2-agonist or antagonist within 14 days before the scheduled procedure.
- patients received an IV opioid within 1 h, or an oral or IM opioid within 4 h of the start of study drug administration.
- Patients who are allergic to Dexmedetomidine or alpha 2-agonists.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Dexmeditomedine Dexmeditomedine Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.
- Primary Outcome Measures
Name Time Method verbal analogue scale 1 hour assessment of pain using VAS score
Degree of sedation 1 hour It will be measured and recorded by using the Ramsay sedation score.
- Secondary Outcome Measures
Name Time Method patient satisfaction 24 hours assessment of patient satisfaction by 4 point scale
Trial Locations
- Locations (1)
National Cancer Institute-Egypt
🇪🇬Cairo, Egypt